{Reference Type}: Journal Article
{Title}: Long Non-Coding RNA FLG-AS1 Inhibits Cervical Cancer Progression through Negatively Modulating miR-147b.
{Author}: Gao M;Pang X;Ni S;Wei Z;Li D;
{Journal}: Ann Clin Lab Sci
{Volume}: 54
{Issue}: 2
{Year}: 2024 Mar
{Factor}: 1.18
{Abstract}: <B>OBJECTIVE: </B>The study investigated the association between FLG-AS1 and cervical cancer prognosis and the interaction mechanism between FLG-AS1 and miR-147b in order to identify potential therapeutic targets for cervical cancer.<BR><B>METHODS: </B>In this study, tissue samples and clinicopathological characteristics were obtained from 125 cervical cancer patients. FLG-AS1 expression levels in the samples were detected by polymerase chain reaction assay. CCK-8 and Transwell assays were used to evaluate FLG-AS1's impact on cervical cancer cell proliferation and metastasis. The mechanism of action of FLG-AS1 and miR-147b was probed by a dual luciferase reporter gene assay. The prognostic nature of FLG-AS1 in cervical cancer was explored by a series of statistical approaches.<BR><B>RESULTS: </B>In cervical cancer cells and tissues, FLG-AS1 expression is markedly downregulated. FLG-AS1 inhibits the activities of cervical cancer cells by negatively regulating miR-147b expression. Patients with cervical cancer have a poor prognosis when FLG-AS1 expression is low.<BR><B>CONCLUSIONS: </B>FLG-AS1 may be considered as a novel cervical cancer prognostic biomarker candidate, which affects cancer cell progression by negatively regulating miR-147b.